Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$29.89 ▲ +0.23
(+0.78%)
MKT CAP: $2.35B • VOL: 918.9K
52W L $22 52W H $45
CLDX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.5M | $7.0M | $6.9M |
| YoY Revenue Growth % | -78.0% | +2.0% | — |
| Gross Profit | $1.3M | $6.8M | — |
| Gross Margin % | 87.1% | 97.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$287.4M | -$195.1M | -$154.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$258.8M | -$157.9M | -$141.4M |
| EBITDA (Normalized) | -$285.2M | -$193.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$210.9M | -$157.8M | -$107.3M |
| Capital Expenditures (CapEx) | $2.7M | $1.9M | — |
| Free Cash Flow (FCF) | -$213.7M | -$159.7M | -$107.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -21.4% | — |
| Cash & Short-Term Equivalents | $28.9M | $28.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $527.2M | $747.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CLDX.